A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

IRB/UVA Tracking #
20636
Contact
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Karen Ballen
Status
OPEN TO ACCRUAL
Ages
Adult